

ADDF-HARRINGTON SCHOLAR AWARD

FUNDING OPPORTUNITY

OVERVIEW

The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute® have partnered to accelerate the translation of academic discoveries into medicines for **treating, preventing, or curing patients with Alzheimer's disease and related dementias.**

SUCCESSFUL APPLICANTS WILL RECEIVE:


- \$600,000 guaranteed grant award;
- **Drug and business development support** from Harrington's Therapeutics Development advisors;
- Opportunity to qualify for **investment funds**

Grant term: 2 years

Eligibility: MD or PhD researchers in the U.S., Canada and U.K.

THE HARRINGTON ADVANTAGE

We work with our Scholars to de-risk and advance their discoveries into the clinic. IP rights are retained by the Scholar/Institution.



INDUSTRY LEADERSHIP EXPERIENCE

Merck | Bristol Myers Squibb | Schering-Plough | Forest Laboratories
GlaxoSmithKline | Johnson & Johnson | AstraZeneca | Allergan

PROPOSALS OF INTEREST



Novel approaches to treat Alzheimer's disease and related dementias. Of particular interest are targets related to proteostasis and senescence.

IMPORTANT DATES

APRIL 1, 2024

Call opens for Letter of Intent

JUNE 3, 2024

Letter of Intent submission deadline

AUGUST 26, 2024

Full application deadline for those invited

MARCH 2025

Scholars announced

LEARN MORE & APPLY:

HarringtonDiscovery.org/ADDF-Harrington

QUESTIONS?

Questions@HarringtonDiscovery.org

Harrington Discovery Institute

 University Hospitals | Cleveland, Ohio

